NLS-2

Phase 3Small molecule

NNLS Pharmaceutics

NLS-2 is one of 8 small molecule programs targeting Narcolepsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NarcolepsyNot yet recruiting

NarcolepsyPhase 3

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Narcolepsy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Romazicon

CConrado Roberto Hoffmann Filho

NLS-2

1 4

E2086

Eisai

Phase 2

2 5

Xyrem

Jazz Pharmaceuticals

Preclinical

—6

Wakix

HHarmony Biosciences Management, Inc.

Preclinical

1 7

Lu AH69593

Lundbeck

Phase 1

1 8

JZP441

Jazz Pharmaceuticals

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Narcolepsy1 trial

A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1

Not yet recruiting·NNLS Pharmaceutics·Phase 3·NCT05914194·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NLS-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NLS-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NLS-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NLS Pharmaceutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNLS Pharmaceutics

NLS-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Narcolepsy1 trial

References

Drug Info

Quick Facts

Related News